Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100337 | 1.00 | CHEK1 (0.37) | CHEK1DAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL30481014 | 0.81 | — | — | |
| SCHEMBL1749731 | 0.81 | — | — | |
| SCHEMBL2327924 | 0.77 | CRBN (0.39) | CHEK1DAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL2449272 | 0.73 | — | — | |
| SCHEMBL1303005 | 0.73 | — | — | |
| SCHEMBL30672241 | 0.73 | — | — | |
| SCHEMBL30129657 | 0.73 | — | — | |
| SCHEMBL19553234 | 0.73 | DAPK3 (0.47) | CHEK1DAPK3PRKD3MAP4K4CSF1R | |
| SCHEMBL30172972 | 0.73 | ASIC3 (0.40) | CHEK1DAPK3PRKD3MAP4K4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | claimed |
| CN-110167937-B | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB生物制药私人有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20250249017-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS INCLUDING NALTREXONE FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250249018-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS INCLUDING BUPROPION FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250249016-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12303514-B2 | Immediate and controlled release appetite suppressant compositions for weight loss | Red Mountain Med Spa, LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6117849-A | SYNERGISTIC INHIBITORY EFFECTS ON REPLICATION OF HUMAN-IMMUNODEFICIENCY VIRUS 1 & 2 IN VITRO AND IN VIVO, PARTICULARLY ON REVERSE TRANSCRIPTASE; HIGH THERAPEUTIC INDEX | SYMBIO HERBORN GROUP GMBH & CO. (DE) | 2000-09-12 | — | — | US | disclosed |
| EP-0530579-B1 | Condensed pyrimidine derivatives antitumor agents | EISAI CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| EP-0827964-A2 | S-(+)-adenosylmethionine and 3'-azido-2',3'-dideoxy-nucleo-side complexes as potent inhibitors of HIV-replication | The Symbio Herborn Group GmbH & Co. (DE) | 1998-03-11 | — | — | EP | disclosed |
| US-5688800-A | ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5554615-A | ANTITUMOR | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0530579-A1 | Condensed pyrimidine derivatives antitumor agents | Eisai Co., Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | CCR1, AOC1, NOD1 | CHEK1 2790/4885DAPK3 847/4885PRKD3 2014/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | CHEK1 722/4885DAPK3 1628/4885PRKD3 1935/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | CHEK1 632/4885DAPK3 1762/4885PRKD3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.